The largest community of pharma leaders

First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy

STRASBOURG, France–(BUSINESS WIRE)– #Transgene–Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that a first patient with head and neck cancer has been dosed with the Company’s innovative individualized immunotherapy, TG4050. This novel therapeutic vaccine is based on Transgene’s myvac® technology platform, which leverages cutting-edge Artificial Intelligence (AI) capabilities to custom

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles